| # | Drug | Count |
|---|---|---|
| 0 | CANNABIDIOL | 18 |
| 1 | DINUTUXIMAB | 18 |
| 2 | FAMOTIDINE | 18 |
| 3 | GABAPENTIN | 18 |
| 4 | LORAZEPAM | 18 |
| 5 | LORLATINIB | 17 |
| 6 | TEMOZOLOMIDE | 17 |
| 7 | DEXAMETHASONE SODIUM PHOSPHATE | 16 |
| 8 | METHADONE | 16 |
| 9 | METHADONE HYDROCHLORIDE | 16 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DINUTUXIMAB | 18 | 0.0210 |
| 1 | LORLATINIB | 17 | 0.0023 |
| 2 | DEXAMETHASONE SODIUM PHOSPHATE | 16 | 0.0015 |
| 3 | METHADONE HYDROCHLORIDE | 16 | 0.0015 |
| 4 | TEMOZOLOMIDE | 17 | 0.0008 |
| 5 | CANNABIDIOL | 18 | 0.0007 |
| 6 | IRINOTECAN HYDROCHLORIDE | 7 | 0.0005 |
| 7 | DACTINOMYCIN | 1 | 0.0005 |
| 8 | METHADONE | 16 | 0.0004 |
| 9 | HYDROMORPHONE HYDROCHLORIDE | 14 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 20 |
| 1 | Benzodiazepine [EPC] | 18 |
| 2 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 18 |
| 3 | Histamine-2 Receptor Antagonist [EPC] | 18 |
| 4 | Kinase Inhibitor [EPC] | 17 |
| 5 | Corticosteroid [EPC] | 2 |
| 6 | Platinum-based Drug [EPC] | 2 |
| 7 | Actinomycin [EPC] | 1 |
| 8 | Androgen Receptor Inhibitor [EPC] | 1 |
| 9 | Calcium [EPC] | 1 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 18 | 0.0166 |
| 1 | Actinomycin [EPC] | 1 | 0.0005 |
| 2 | Histamine-2 Receptor Antagonist [EPC] | 18 | 0.0001 |
| 3 | Alkylating Drug [EPC] | 20 | 0.0001 |
| 4 | Provitamin D2 Compound [EPC] | 1 | 0.0000 |
| 5 | Kinase Inhibitor [EPC] | 17 | 0.0000 |
| 6 | Benzodiazepine [EPC] | 18 | 0.0000 |
| 7 | Androgen Receptor Inhibitor [EPC] | 1 | 0.0000 |
| 8 | Platinum-based Drug [EPC] | 2 | 0.0000 |
| 9 | Calcium [EPC] | 1 | 0.0000 |